Literature DB >> 31782573

Gartanin is a novel NEDDylation inhibitor for induction of Skp2 degradation, FBXW2 expression, and autophagy.

Victor Pham1,2, Raymond Rendon1, Vinh X Le1, Matthew Tippin1, Dong-Jun Fu1, Thanh H Le1, Marvin Miller1, Ericka Agredano1, Jose Cedano1, Xiaolin Zi1,2.   

Abstract

Gartanin, a 4-prenylated xanthone, has been identified from the purple mangosteen fruit as a potent growth inhibitor of various cancer cell lines, including prostate cancer. However, much of Gartanin's anticancer mechanism remains unknown. We have discovered that Gartanin docked onto the regulatory subunit of the precursor cell-expressed developmentally downregulated 8 (NEDD8)-activating enzyme (NAE) complex and next to the NEDD8 binding complex, which leads to inhibit NEDD8 conjugations to both Cullin1 and Ubc12 in prostate cancer cell lines and Ubc12 NEDDylation in an in vitro assay. The S phase kinase-associated protein (Skp2) and F-box and WD-repeat domain-containing 2 (FBXW2), the NEDD8 family members of E3 ubiqutin ligases, were also downregulated and upregulated by Gartainin, respectively. Knock-down of NEDD8 expression by short harpin (Sh) RNAs blocked or attenuated these effects of Gartainin. Finally, Gartanin demonstrated its ability to inhibit growth of prostate cancer lines via autophagy initiation. Our data support that Gartanin is a naturally occurring NEDDylation inhibitor and deserves further investigation for prostate cancer prevention and treatment.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Gartanin; Skp2; chemoprevention; neddylation; prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31782573      PMCID: PMC6946862          DOI: 10.1002/mc.23140

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  40 in total

1.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

2.  Overactivated neddylation pathway as a therapeutic target in lung cancer.

Authors:  Lihui Li; Mingsong Wang; Guangyang Yu; Ping Chen; Hui Li; Dongping Wei; Ji Zhu; Li Xie; Huixun Jia; Jieyi Shi; Chunjie Li; Wantong Yao; Yanchun Wang; Qiang Gao; Lak Shin Jeong; Hyuk Woo Lee; Jinha Yu; Fengqing Hu; Ju Mei; Ping Wang; Yiwei Chu; Hui Qi; Meng Yang; Ziming Dong; Yi Sun; Robert M Hoffman; Lijun Jia
Journal:  J Natl Cancer Inst       Date:  2014-05-22       Impact factor: 13.506

3.  Squamous cell carcinoma related oncogene/DCUN1D1 is highly conserved and activated by amplification in squamous cell carcinomas.

Authors:  Inderpal Sarkaria; Pornchai O-charoenrat; Simon G Talbot; Pabbathi G Reddy; Ivan Ngai; Ellie Maghami; Kepal N Patel; Benjamin Lee; Yoshihiro Yonekawa; Maria Dudas; Andrew Kaufman; Russell Ryan; Ronald Ghossein; Pulivarthi H Rao; Archontoula Stoffel; Y Ramanathan; Bhuvanesh Singh
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 4.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

5.  Clinical significance of SCCRO (DCUN1D1) in prostate cancer and its proliferation-inhibiting effect on Lncap cells.

Authors:  Z-H Zhang; J Li; F Luo; Y-S Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-10       Impact factor: 3.507

Review 6.  The SCF-type E3 Ubiquitin Ligases as Cancer Targets.

Authors:  Kyoko Kitagawa; Masatoshi Kitagawa
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

7.  A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.

Authors:  Shailender Bhatia; Anna C Pavlick; Peter Boasberg; John A Thompson; George Mulligan; Michael D Pickard; Hélène Faessel; Bruce J Dezube; Omid Hamid
Journal:  Invest New Drugs       Date:  2016-04-08       Impact factor: 3.850

8.  Gartanin induces cell cycle arrest and autophagy and suppresses migration involving PI3K/Akt/mTOR and MAPK signalling pathway in human glioma cells.

Authors:  Ming Luo; Qingyu Liu; Mingliang He; Zhiling Yu; Rongbiao Pi; Min Li; Xiaohong Yang; Shengnan Wang; Anmin Liu
Journal:  J Cell Mol Med       Date:  2016-08-05       Impact factor: 5.310

9.  The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor.

Authors:  Jie Xu; Weihua Zhou; Fei Yang; Guoan Chen; Haomin Li; Yongchao Zhao; Pengyuan Liu; Hua Li; Mingjia Tan; Xiufang Xiong; Yi Sun
Journal:  Nat Commun       Date:  2017-01-16       Impact factor: 14.919

10.  FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation.

Authors:  Fei Yang; Jie Xu; Hua Li; Mingjia Tan; Xiufang Xiong; Yi Sun
Journal:  Nat Commun       Date:  2019-03-27       Impact factor: 14.919

View more
  4 in total

Review 1.  Polyphenol-Mediated Autophagy in Cancer: Evidence of In Vitro and In Vivo Studies.

Authors:  Monica Benvenuto; Loredana Albonici; Chiara Focaccetti; Sara Ciuffa; Sara Fazi; Loredana Cifaldi; Martino Tony Miele; Fernando De Maio; Ilaria Tresoldi; Vittorio Manzari; Andrea Modesti; Laura Masuelli; Roberto Bei
Journal:  Int J Mol Sci       Date:  2020-09-10       Impact factor: 5.923

2.  Inhibition of CDK2/CyclinE1 by xanthones from the mangosteen (Garcinia mangostana): a structure-activity relationship study.

Authors:  Mirielle C Nauman; Restituto Tocmo; Bhaskar Vemu; Jacob P Veenstra; Jeremy J Johnson
Journal:  Nat Prod Res       Date:  2020-07-21       Impact factor: 2.861

Review 3.  Emerging Roles of SKP2 in Cancer Drug Resistance.

Authors:  Ting Wu; Xinsheng Gu; Hongmei Cui
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

4.  Kava root extracts hinder prostate cancer development and tumorigenesis by involvement of dual inhibition of MAO-A and LSD1.

Authors:  Xuesen Li; Liankun Song; Shan Xu; Matthew Tippin; Shuan Meng; Jun Xie; Edward Uchio; Xiaolin Zi
Journal:  J Transl Genet Genom       Date:  2021-05-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.